Since then, after continuing to Shenzhen and Anhui, Shanghai has also made efforts in mergers and acquisitions.It is worth mentioning that the Action Plan also mentioned that if the "chain owner" enterprises carry out mergers and acquisitions around the key links of the industrial chain through enterprise venture capital (CVC), the establishment of CVC funds will be included in the fast track. At the same time, government investment funds can participate in M&A fund investment through common shares, preferred shares and convertible bonds, and make appropriate profits.In this regard, Bu Rixin believes that "chain owners" enterprises, as market-oriented institutions, set up CVC funds and will carry out horizontal and vertical mergers and acquisitions around the upstream and downstream of key industrial chains. "This kind of M&A will help chain-owner enterprises to expand their market scale and enhance their market competitiveness, which is the most in line with the logic of M&A and the basic logic of the Action Plan to encourage chain-owner enterprises to set up CVC funds."
At the end of the year, Shanghai launched a big action in the field of mergers and acquisitions. Today, the General Office of the Shanghai Municipal People's Government issued the Action Plan for Shanghai to Support the Merger and Reorganization of Listed Companies (2025-2027) (hereinafter referred to as the Action Plan).In addition to the integrated circuit design industry, Shanghai will also set up a M&A fund for the biomedical industry with a scale of 10 billion yuan.Big move! Two billion M&A and restructuring funds in Shanghai have come to target the chip and pharmaceutical industries.
In terms of the amount, it is necessary to form a M&A transaction scale of 300 billion yuan, activate the total assets to exceed 2 trillion yuan, and gather 3-5 professional M&A fund managers with strong industry influence. The plan also proposes to make good use of the 10 billion yuan integrated circuit design industry M&A fund and set up a 10 billion yuan biomedical industry M&A fund."Because the industry is a typical' big money' industry, that is, high risk, long cycle and burning money, the nature of biomedicine also determines that it needs mergers and acquisitions in the current environment to become bigger and stronger."Among them, Chengdu Ruiyuan Semiconductor is mainly engaged in the research and development, design, packaging and sales of power management chips, and one of its main products is DC/DC chips. A-share listed companies include Jingfeng Mingyuan, Fumanwei, Shanghai Beiling and Xidiwei, all of which have certain market share and competitiveness in the DC/DC chip market.
Strategy guide 12-14
Strategy guide 12-14
Strategy guide
12-14
Strategy guide 12-14
Strategy guide
12-14
Strategy guide
12-14
Strategy guide
12-14